SCHEMBL21334724

SCHEMBL21334724

CC(=O)OC[C@H]1C[C@@H]1C(=O)Cl

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.36
LMNA P02545 1/20 0.36
HSD17B10 Q99714 1/20 0.36
NLRP3 Q96P20 2/20 0.34
PDK1 Q15118 1/20 0.31
TSHR P16473 2/20 0.30
GABRR1 P24046 2/20 0.30
GABRR2 P28476 1/20 0.30
PGR P06401 1/20 0.30
CHRM2 P08172 1/20 0.30
CHRM4 P08173 1/20 0.30
HTR1A P08908 1/20 0.30
CHRM5 P08912 1/20 0.30
CHRM1 P11229 1/20 0.30
CHRNB2 P17787 1/20 0.30
CHRM3 P20309 1/20 0.30
TBXA2R P21731 1/20 0.30
CHRNB4 P30926 1/20 0.30
CHRNA3 P32297 1/20 0.30
CHRNA7 P36544 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20517882 1.00 ALDH1A1 (0.36) ALDH1A1LMNAHSD17B10NLRP3PDK1
SCHEMBL23429422 1.00 ALDH1A1 (0.36) ALDH1A1LMNAHSD17B10NLRP3PDK1
SCHEMBL20525100 0.83 GABRR1 (0.48) ALDH1A1LMNAHSD17B10GABRR1GABRR2
SCHEMBL21334725 0.83 GABRR1 (0.48) ALDH1A1LMNAHSD17B10GABRR1GABRR2
SCHEMBL20518042 0.83 GABRR1 (0.48) ALDH1A1LMNAHSD17B10GABRR1GABRR2
SCHEMBL11211680 0.79 ALDH1A1 (0.46) ALDH1A1LMNAHSD17B10TSHR
SCHEMBL3120876 0.78
SCHEMBL13003493 0.76
SCHEMBL14026353 0.76
SCHEMBL24912279 0.75 ALDH1A1 (0.43) ALDH1A1LMNAHSD17B10NLRP3PDK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11034692-B1 Naphthyridines as inhibitors of HPK1 GENENTECH, INC. (US) 2021-06-15 US disclosed
US-10407424-B2 Naphthyridines as inhibitors of HPK1 GENENTECH, INC. (US) 2019-09-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10407424-B2 Naphthyridines as inhibitors of HPK1 NEK1, NEK5, NEK11 ALDH1A1 4630/4885LMNA 2129/4885HSD17B10 1905/4885
US-11034692-B1 Naphthyridines as inhibitors of HPK1 NEK1, NEK5, NEK11 ALDH1A1 4630/4885LMNA 2129/4885HSD17B10 1905/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.